Targeted synthetic drugs

AB1618-HPR ENHANCING HERPES ZOSTER VACCINATION AMONG ADULT RHEUMATOLOGY PATIENTS ON JAK INHIBITORS IN KUWAIT: ASSESSING CURRENT UPTAKE AND IDENTIFYING IMPROVEMENT OPPORTUNITIES - A QUALITY IMPROVEMENT INITIATIVE
M. Khudadah, G. Aldabie, S. Al Naqeeb, K. S. M. E. M. Mohammed

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2184; DOI: 10.1136/annrheumdis-2024-eular.2590
AB1446 ASSOCIATION OF GENETICALLY PROXIED JANUS KINASE INHIBITOR TARGETS WITH CARDIOVASCULAR RISK: A DRUG-TARGET MENDELIAN RANDOMIZATION STUDY
L. Dai, Q. Y. Song, Y. W. Zou, Y. Su, L. W. Su, J. D. MA, J. Pan, Z. M. Ouyang, Y. Lu, T. Wu, J. Z. Lin, P. W. Jia, H. W. Zheng, J. Dai

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2080-2081; DOI: 10.1136/annrheumdis-2024-eular.3664
AB1479 NON-ANTI-TNF BIOLOGIC AND TARGETED THERAPIES ARE NOT ASSOCIATED WITH INCREASED RISK OF TUBERCULOSIS IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: A COHORT STUDY IN AN ENDEMIC AREA
E. K. M. Wong, H. So, C. H. Lam, C. K. Lau, Y. Leung, Y. Q. Yip, L. S. Tam

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2105; DOI: 10.1136/annrheumdis-2024-eular.5209
AB1349 BIOLOGIC AND TARGETED SYNTHETIC DRUGS MANAGEMENT IN RHEUMATOID ARTHRITIS AFTER IMPLEMENTATION OF A COMMUNITY OPTIMIZATION PROTOCOL
E. Aurrecoechea, J. L. Martín-Varillas, A. Colón-López de Dicastillo, S. Lorenzo-Martín, D. Gómez-Gómez, B. Ayestarán-González, R. Blanco

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2027; DOI: 10.1136/annrheumdis-2024-eular.6102
AB1375 TOFACITINIB AS ALTERNATIVE TO TNF BLOCKERS IN REFRACTORY ANTERIOR UVEITIS - AN OBSERVATIONAL STUDY
N. Gupta, D. Mahajan

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2040; DOI: 10.1136/annrheumdis-2024-eular.304
AB1390 BARICITINIB FOR THE TREATMENT OF RELAPSING POLYCHONDRITIS: A COHORT STUDY
Z. Zhang, Y. Wang

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2049; DOI: 10.1136/annrheumdis-2024-eular.1552
AB1394 MANAGEMENT OF PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOUR/PIGMENTED VILLONODULAR SYNOVITIS IN THE ERA OF SYSTEMIC TARGETED THERAPY
M. Cochard, M. Chevalerias, D. Waast, V. Crenn, B. Le Goff

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2051; DOI: 10.1136/annrheumdis-2024-eular.3319
AB1403 MULTICENTER STUDY ON RHEUMATOLOGICAL MANIFESTATIONS IN CANCER PATIENTS TREATED WITH IMMUNOTHERAPY
M. Garijo Bufort, M. Aguilar Zamora, K. Arévalo Ruales, C. Molina Almela, M. C. López González, M. Andrés, N. Martínez Banaclocha, R. González Mazario

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2055-2056; DOI: 10.1136/annrheumdis-2024-eular.5523
AB1408 JANUS KINASE INHIBITORS IN REFRACTORY INFLAMMATORY OCULAR SURFACE PATHOLOGY. MULTICENTER STUDY AND LITERATURE REVIEW
L. Sanchez-Bilbao, J. L. Martín-Varillas, V. Calvo-Río, M. D. M. Esteban-Ortega, S. Munoz-Fernández, J. L. Álvarez-Vega, I. Torre-Salaberri, A. Urruticoechea-Arana, E. Valls-Pascual, R. Demetrio-Pablo, R. Blanco

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2058; DOI: 10.1136/annrheumdis-2024-eular.6303
AB1245 AVACOPAN IN ANCA-ASSOCIATED VASCULITIS RECEIVED INTENSIFIED INDUCTION THERAPY WITH CYCLOPHOSPHAMIDE PLUS RITUXIMAB – RETROSPECTIVE OBSERVATION TWO-CENTRE STUDY OF 30 PATIENTS
G. Assmann, A. El-Baraa, K. Peter, T. Ryszard, R. Joerg, M. Schmidt, P. Lamprecht

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1962; DOI: 10.1136/annrheumdis-2024-eular.2573

Main menu

Targeted synthetic drugs

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Targeted synthetic drugs

Pages